Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy aloneMichael Gnant, Torsten O. Nielsen, Brigitte Mlineritsch et al.|Annals of Oncology|2013Cited by 403
Abstract S2-06: Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in the ABCSG-8 studyMichael Knauer, Michael Gnant, Christine Gruber et al.|Cancer Research|2015Cited by 21
Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the ABCSG Trial 5Zsuzsanna Bagó-Horváth, Martin Filipits, Margaretha Rudas et al.|Clinical Cancer Research|2020Cited by 7